Nuvilex Inc. (NASDAQ:PMCB) Short Interest Update

Nuvilex Inc. (NASDAQ:PMCB) saw a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 140,630 shares, a drop of 21.7% from the January 29th total of 179,649 shares. Approximately 1.5% of the company’s stock are short sold. Based on an average daily trading volume, of 184,312 shares, the short-interest ratio is currently 0.8 days. Based on an average daily trading volume, of 184,312 shares, the short-interest ratio is currently 0.8 days. Approximately 1.5% of the company’s stock are short sold.

Insider Transactions at Nuvilex

In other Nuvilex news, CEO Joshua Silverman acquired 40,000 shares of Nuvilex stock in a transaction dated Wednesday, January 7th. The stock was bought at an average cost of $0.83 per share, with a total value of $33,200.00. Following the acquisition, the chief executive officer owned 416,250 shares of the company’s stock, valued at approximately $345,487.50. The trade was a 10.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders purchased 110,000 shares of company stock valued at $89,000. Company insiders own 10.33% of the company’s stock.

Analyst Ratings Changes

PMCB has been the topic of several recent analyst reports. Wall Street Zen upgraded Nuvilex to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings restated a “sell (d)” rating on shares of Nuvilex in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Nuvilex Stock Down 2.3%

Nuvilex stock traded down $0.02 during mid-day trading on Wednesday, reaching $0.69. 133,952 shares of the company’s stock were exchanged, compared to its average volume of 264,856. The company has a fifty day moving average of $0.79 and a 200-day moving average of $0.89. Nuvilex has a twelve month low of $0.63 and a twelve month high of $1.82. The company has a market cap of $7.44 million, a P/E ratio of -0.50 and a beta of 0.33.

Nuvilex (NASDAQ:PMCB) last issued its quarterly earnings data on Thursday, December 18th. The company reported ($0.32) EPS for the quarter.

About Nuvilex

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.